Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma - 05/04/18
Doi : 10.1016/j.jaci.2018.01.008
Roma Sehmi, PhD a, Hui Fang Lim, MRCP(UK) a, ∗, Manali Mukherjee, PhD a, ∗, Chynna Huang, RRT a, Katherine Radford, MSc a, Paul Newbold, PhD b, Louis-Philippe Boulet, MD c, Delbert Dorscheid, MD, PhD d, James G. Martin, MD, DSc e, Parameswaran Nair, MD, PhD a 
a the Division of Respirology, McMaster University, Hamilton, Ontario, Canada
b MedImmune LLC, Gaithersburg, Md
c Institut universitaire de cardiologie et de pneumologie de Québec, Quebec City, Quebec, Canada
d University of British Columbia, Vancouver, British Columbia, Canada
e Meakins-Christie Laboratories, Research Institute of the McGill University Health Center, Montreal, Quebec, Canada
| This substudy was funded by AstraZeneca and AllerGen NCE. AstraZeneca and AllerGen NCE did not have any role in the design and conduct of the substudy, interpretation of data, or preparation of the early drafts of the manuscript. Editorial support, including editing and submission of the manuscript, was funded by AstraZeneca. All authors had full access to all data in the study and had final responsibility for the decision to submit for publication. |
|
| Disclosure of potential conflicts of interest: R. Semi has received research support from AstraZeneca. P. Newbold is an employee of MedImmune LLC. L.-P. Boulet has received research support from AIM Therapeutics, Amgen, Asmacure, AstraZeneca, Axikin, Boehringer Ingelheim, GlaxoSmithKline, Hoffman La Roche, Merck, Novartis, Ono Pharma, Sanofi, and Takeda; is an advisory board member for AstraZeneca, Metapharm, and Novartis; has received conference support from AstraZeneca, GlaxoSmithKline, Merck, Novartis, and Takeda; and has received nonprofit grants for production of educational materials from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck Frosst, and Novartis. J. G. Martin has acted as an advisor to AstraZeneca. P. Nair reports research support, consultancy fees, and speaker fees from AstraZeneca; research support from Boehringer Ingelheim, GlaxoSmithKline, Novartis, Sanofi, and Teva; consultancy fees from Inflamax, Knopp, Roche, Sanofi, and Teva; speaker fees from Novartis and Teva; and acting as a committee member for Roche, Sanofi, and Teva. The rest of the authors declare that they have no relevant conflicts of interests. |
© 2018
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 141 - N° 4
P. 1529 - avril 2018 Retour au numéro
Article précédent
- Impact of food allergy on the growth of children with moderate-severe atopic dermatitis
- Rekha D. Jhamnani, Samara Levin, Marjohn Rasooly, Kelly D. Stone, Joshua D. Milner, Celeste Nelson, Tom DiMaggio, Nina Jones, Anthony L. Guerrerio, Pamela A. Frischmeyer-Guerrerio
- Age-dependent effect of ambient ozone on emergency asthma hospitalizations in Hong Kong
- Yuanrong Dai, Hong Qiu, Shengzhi Sun, Yang Yang, Hualiang Lin, Linwei Tian
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?